Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones
|
|
- Liliana Gwen Wilcox
- 6 years ago
- Views:
Transcription
1 CJASN epress. Published on August 8, 2013 as doi: /CJN Article Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones David S. Goldfarb,* Patricia A. MacDonald, Lhanoo Gunawardhana, Solomon Chefo, and Lachy McLean Summary Background and objectives Higher urinary uric acid excretion is a suspected risk factor for calcium oxalate stone formation. Febuxostat, a xanthine oxidoreductase inhibitor, is effective in lowering serum urate concentration and urinary uric acid excretion in healthy volunteers and people with gout. This work studied whether febuxostat, compared with allopurinol and placebo, would reduce 24-hour urinary uric acid excretion and prevent stone growth or new stone formation. Design, setting, participants, & measurements In this 6-month, double-blind, multicenter, randomized controlled trial, hyperuricosuric participants with a recent history of calcium stones and one or more radio-opaque calcium stone $3 mm (as seen by multidetector computed tomography) received daily febuxostat at 80 mg, allopurinol at 300 mg, or placebo. The primary end point was percent change from baseline to month 6 in 24-hour urinary uric acid. Secondary end points included percent change from baseline to month 6 in size of index stone and change from baseline in the mean number of stones and 24-hour creatinine clearance. Results Of 99 enrolled participants, 86 participants completed the study. Febuxostat led to significantly greater reduction in 24-hour urinary uric acid (258.6%) than either allopurinol (236.4%; P=0.003) or placebo (212.7%; P,0.001). Percent change from baseline in the size of the largest calcium stone was not different with febuxostat compared with allopurinol or placebo. There was no change in stone size, stone number, or renal function. No new safety concerns were noted for either drug. Conclusions Febuxostat (80 mg) lowered 24-hour urinary uric acid significantly more than allopurinol (300 mg) in stone formers with higher urinary uric acid excretion after 6 months of treatment. There was no change in stone size or number over the 6-month period. Clin J Am Soc Nephrol 8: ccc ccc, doi: /CJN Introduction The prevalence of kidney stones is increasing, regardless of sex or race. The reported prevalence of kidney stones during was 5.2% (1). During , this had risen to 8.8% (2), an increase of 69%. Approximately 50% of first-time stone formers will have a recurrent stone within 5 years, despite preventive therapy (3). For patients managed with minimally invasive procedures, the risk of recurrence after 5 years is 63% (4). There remains a need to develop medical treatment modalities that can reduce the likelihood of recurrent nephrolithiasis. Calcium oxalate (CaOx) is the predominant component of kidney stones (5). Elevated urinary uric acid (uua) or hyperuricosuria is a suspected risk factor for CaOx stone formation, because up to one third of CaOx stone formers have higher uua excretion (6 10). This association is further supported by studies showing that treatment with the urate-lowering drug allopurinol, a xanthine oxidoreductase inhibitor (XORI), led to reduced rates of stone recurrence (6 8,10). Febuxostat, a newer XORI, is highly efficacious in reducing serum urate levels (suas) (11 13). It also reduces uua levels in healthy volunteers (14) and in individuals with hyperuricemic gout (15). Therefore, febuxostat may provide an alternative or superior treatment to allopurinol in stone prevention. This study evaluated treatment with febuxostat compared with allopurinol (at the approved and previously studied doses for higher uua excretion) or placebo in the reduction of 24-hour uua excretion in participants with higher uua and a recent history of kidney stones. Materials and Methods Study Design and Participant Selection This was a phase 2, 6-month, multisite, United Statesbased, randomized febuxostat and allopurinol- and placebo-controlled double blind trial (clinicaltrials.gov NCT ). The study was conducted in compliance with Institutional Review Board regulations, Good Clinical Practice guidelines, and the Declaration of Helsinki. *Nephrology Section, New York Harbor VA Medical Center, and Division of Nephrology, New York University Langone Medical Center, New York, New York; Global Medical Affairs, Takeda Pharmaceuticals International, Deerfield, Illinois; Clinical Science, and Statistics, Takeda Global Research & Development Center, Inc., Deerfield, Illinois; and Experimental Medicine, Takeda California, San Diego, California Correspondence: Dr. David S. Goldfarb, New York University School of Medicine, Nephrology Division, New York Harbor VA Healthcare System, 423 East 23rd Street/ 111G, New York, NY david. goldfarb@nyumc.org Vol 8 November, 2013 Copyright 2013 by the American Society of Nephrology 1
2 2 Clinical Journal of the American Society of Nephrology All participants signed informed consent and Health Insurance Portability and Accountability Act of 1996 forms before initiation of any study procedures. Men and women with higher uua excretion (.700 mg/24 h) over the age of 18 years with a recent (#5 years) history of kidney stones and one or more radio-opaque calcium kidney stone $3 mm in its longest in-plane diameter at screening were enrolled. Radio-opacity was judged on the abdominal scout film, taken at the beginning of the computed tomograph, which is equivalent to a plain abdominal film. Whether stones were composed of calcium oxalate or calcium phosphate could not be determined, but the former presumably constituted the majority. Because the qualifying stone was radio-opaque, uric acid composition was very unlikely. If premenopausal, women were using an accepted form of contraception and could not be pregnant or lactating. Participants were excluded if they had any of the following criteria: gout, secondary hyperuricemia, or hyperparathyroidism; higher urinary calcium excretion (.250 mg/d for women and.300 mg/d for men or.4 mg/kg per day if body weight was $75 kg for men and $62.5 kg for women); a history of xanthinuria, inflammatory bowel disease, or bowel resection; renal tubular acidosis; cancer in the past 5 years; febuxostat, allopurinol, or probenecid prescription in the past 2 years; a known hypersensitivity to allopurinol or febuxostat; any other clinically relevant conditions that would interfere with participation in the study; or use of excluded medications (salicylates.325 mg/d, azathioprine, mercaptopurine, theophylline, colchicine, pyrazinamide, sulfamethoxazole/trimethoprim, or losartan). Participants were not excluded if they were taking potassium citrate. Participants receiving diuretics were to be on a stable dose for $30 days before screening. Eligible individuals were randomized 1:1:1 to receive once-daily febuxostat (80 mg), allopurinol (300 or 200 mg depending on renal function; 300 mg if creatinine clearance [Ccr] was $60 ml/min or 200 mg if Ccr was $30 to,60 ml/min), or placebo. The presence and size of kidney stones were assessed by multidetector computed tomography (MDCT) (16) at screening and the month 6 or final visit. Abdominal MDCT was done without contrast using a 16+ detector helical scanner with a 30- to 40-cm field of view and a voxel matrix. The patient was positioned supine, and after an abdominal scout scan, axial images were acquired at 1.25-mm slice thickness during a single breath hold. Digital images or hardcopy films (if digital transfer was not available) were then sent to Perceptive Informatics, Inc. (Waltham, MA) for image quality control and assessment. Adjudicated image assessments were performed by blinded, independent radiologists. At screening and on the day before the month 3 and 6 visits, 24-hour urine collections were performed to measure uua and Ccr along with urinary excretion of calcium, oxalate, citrate, creatinine, magnesium, sodium, potassium, sulfate, total protein, and albumin, and to determine ph. Other clinical laboratory assessments, including sua and hepatic enzymes, were performed at screening, day 1, month 3, and month 6. Adverse events (AEs) were recorded using Medical Dictionary for Regulatory Activities terminology. End Points The primary efficacy end point was the percent change from baseline to month 6 in 24-hour uua excretion. Secondary end points were percent change from baseline to month 6 in the in-plane diameter of the largest calcium stone, change from baseline to month 6 in the number of calcium stones, and change from baseline to month 6 in 24-hour measured Ccr. Additional end points included percentage of participants with sua,6.0 mg/dl at month 6, percent change from baseline to months 3 and 6 in sua levels, change from baseline in estimated GFR (egfr) as calculated by the Modification of Diet in Renal Disease Equation (17), and analysis of AEs and serious AEs. Statistical Analyses Efficacy analyses were performed on the full analysis set, which was defined as all randomized participants who received oneormoredoseofstudydrugandhadabaseline24-hour uua.700 mg and one or more calcium stone $3 mminthe largest in-plane diameter. Safety analyses were performed on all participants who received one or more dose of study drug. Descriptive statistics were presented for all variables assessed, and all statistical tests were two-sided and conducted at the 0.05 significancelevel.pairwisecomparisons of febuxostat with allopurinol and placebo for the primary end point and the calcium stone-related secondary efficacy end points were made using the Wilcoxon Mann Whitney rank sum test.for the secondary efficacy end point of change in 24-hour Ccr and additional efficacy end points of change in egfr and percent change in sua, pairwise comparisons between treatment groups were made using contrast statements within the framework of ANOVA with treatment group as a factor. For each primary and secondary end point, the Hochberg method for multiple comparisons was used to ensure that the overall level of significance was maintained for pairwise comparisons of febuxostat with allopurinol and placebo. For the primary analysis, missing 24-hour values from the month 6 visit were imputed with the baseline value if the subject dropped out from the study because of any AE. Otherwise, the missing value was imputed with the last available postbaseline value. Missing data were imputed for only two end points: uua and measured Ccr. Month 6 values were imputed for no more than three subjects per treatment group. The imputation did not significantly influence the results. Data for 24-hour urinary solutes were summarized only for participants with sample values at baseline and month 6. A total of 90 participants (30 per treatment group) was planned for enrollment. This sample size was considered sufficient to characterize the effect of febuxostat on 24-hour uua excretion compared with allopurinol, and it was not designed based on formal power calculations. Results Participants Of 895 individuals screened, 99 individuals were enrolled and randomized (33 per treatment group) (Figure 1). The majority of potential enrollees who failed the screening did so because 24-hour uua levels were,700 mg. Thirteen participants prematurely discontinued: 5, 5, and 3 participants in the febuxostat, allopurinol, and placebo
3 Clin J Am Soc Nephrol 8: ccc ccc, November, 2013 Febuxostat for Hyperuricosuria and Calcium Stones, Goldfarb et al. 3 Figure 1. Flow of participants through the study. AE, adverse event. groups, respectively. Overall, the primary reasons for discontinuation were voluntary withdrawal (6.1%), lost to follow-up (3.0%), AEs (3.0%), and other (1.0%). Demographics and baseline characteristics are listed in Table 1. Most participants were men (85.9), white (86.9%), and over 45 years of age (61.6%). Mean body mass index (BMI) was 32.8 kg/m 2. Mean lifetime history of stone episodes was 10.9, mean largest stone diameter was 9.9 mm, and mean number of stones on MDCT was 5.6. Mean baseline Ccr was 147 ml/min, sua was 6.3 mg/dl, urine calcium excretion was mg/d, and uua was mg/d. No participant in the allopurinol group had moderate renal impairment; therefore, all participants in that group received 300 mg allopurinol daily. Concomitant medications were used by 81 (81.8%) participants. The most frequently used concomitant medications were analgesics (32.3%) and lipid-modifying agents (28.3%). Agents acting on the renin-angiotensin system were used by 18.2% of participants, whereas 5.1% of participants were taking a diuretic. One individual was taking potassium citrate at enrollment and throughout the duration of the study. Efficacy End Points The percent decrease from baseline to month 6 in 24-hour uua was significantly greater in the febuxostat group (258.6%) compared with the allopurinol (236.4%; P=0.003) and placebo (212.7%; P,0.001) groups. At month 3, the percent decreases from baseline for both the febuxostat and allopurinol treatment groups were similar to those values observed at month 6 (Figure 2), suggesting that the impact of either XORI on uua occurred primarily within the first 3 months and then remained stable. Table 2 provides data about stone size and number at baseline and month 6 as well as the change from baseline for each of these parameters. Although the percent change from baseline to month 6 in the diameter of the largest calcium stone detected by MDCT at screening was numerically greater in the febuxostat group, there were no statistically significant differences between the treatment groups in this secondary end point. In addition, there were no significant differences or meaningful changes in the total number of calcium stones between treatment groups from baseline to month 6. The changes from baseline to month 6 in 24-hour Ccr were 29.0, 27.7, and ml/min for the febuxostat, allopurinol, and placebo groups, respectively. These differences were not statistically significant. No changes in serum creatinine levels in any treatment group were observed. At baseline and month 6, the average serum
4 4 Clinical Journal of the American Society of Nephrology Table 1. Demographics and baseline characteristics Baseline Variable Febuxostat 80 mg (n=33) Allopurinol 300 mg (n=33) Placebo (n=33) All Participants (n=99) Sex, men, n (%) 27(81.8) 31(93.9) 27(81.8) 85(85.9) Age, yr, mean (SD) 49.1 (9.6) 46.5 (9.9) 46.5 (11.5) 47.4 (10.3) Race, n (%) 2 (6.1) 0 2 (6.1) 4 (4.0) Asian 3 (9.1) 1 (3.0) 1 (3.0) 5 (5.1) Black/African American 1 (3.0) 0 1 (3.0) 2 (2.0) Native Hawaiian/Pacific Islander Caucasian 26(78.8) 31(93.9) 29(87.9) 86(86.9) Other 1 (3.0) 1 (3.0) 0 2 (2.0) Ethnicity, Hispanic/Latino, n (%) 8 (24.2) 8 (24.2) 3 (9.1) 19 (19.2) Body mass index (kg/m 2 ), mean (SD) 32.9 (5.7) 32.3 (5.8) 33.1 (6.3) 32.8 (5.8) Current smoker, n (%) 4 (12.1) 6 (18.2) 8 (24.2) 18 (18.2) Current alcohol use, n (%) 17(51.5) 16(48.5) 20(60.6) 53(53.5) Creatinine clearance (ml/min), (57.9) (44.3) (53.5) (51.7) mean (SD) Estimated GFR (MDRD; ml/min per 1.73 m 2 ) n (%) $90 6 (18.2) 9 (27.3) 16 (48.5) 31 (31.3) $60 to,90 25 (75.8) 24 (72.7) 16 (48.5) 65 (65.7) $30 to,60 2 (6.1) 0 1 (3.0) 3 (3.0) Lifetime kidney stones episodes, 5.0 (2, 11) 6.0 (3, 10) 5.0 (2, 14) 5.0 (3, 12) median (25th, 75th quartiles) Serum urate (mg/dl), mean (SD) 6.2 (1.63) 6.3 (1.49) 6.3 (1.24) 6.3 (1.45) Serum creatinine (mg/dl), mean (SD) 1.04 (0.18) 1.03 (0.16) 0.97 (0.21) 1.01 (0.19) History of one or more cardiovascular 21 (63.6) 16 (48.5) 20 (60.6) 57 (57.6) condition, n (%) Myocardial infarction 1 (3.0) 1 (3.0) 1 (3.0) 3 (3.0) Cardiac revascularization (3.0) 1 (1.0) Transient ischemic attack 1 (3.0) (1.0) Peripheral vascular disease 2 (6.1) (2.0) Deep vein thrombosis 2 (6.1) (2.0) Angioplasty (3.0) 1 (1.0) Cardiac arrhythmia 1 (3.0) (1.0) Pacemaker or defibrillator 1 (3.0) 1 (3.0) 0 2 (2.0) Congestive heart failure 0 1 (3.0) 0 1 (1.0) History of diabetes mellitus, n (%) 6 (18.2) 5 (15.2) 3 (9.1) 14 (14.1) Hypertension, n (%) 15 (45.5) 10 (30.3) 8 (24.2) 33 (33.3) Hyperlipidemia, n (%) 15(45.5) 10(30.3) 17(51.5) 42(42.4) MDRD, Modification of Diet in Renal Disease. creatinine levels were 1.04 and 1.05 mg/dl, respectively, in the febuxostat group, 1.03 and 1.03 mg/dl, respectively, in the allopurinol group, and 0.97 and 0.97 mg/dl, respectively, in the placebo group. There were no significant differences between treatment groups in the change from baseline to month 6 in egfr. The proportion of participants with sua,6.0 mg/dl at month 6 was significantly greater in the febuxostat (100%) and allopurinol (88.5%) groups compared with the placebo group (44.8%; P#0.001 versus placebo for both febuxostat and allopurinol); the difference between febuxostat and allopurinol was not statistically significant. It is worth noting that there was no entry criterion based on baseline sua in the study, and the overall average baseline sua was 6.3 mg/dl. The percent changes from baseline (reported as least squares mean) to months 3 and 6 were significantly greater in the febuxostat group at either time point (243.3% and 247.3%, respectively) compared with the allopurinol (226.9% and 226.2%, respectively [P,0.001 for both], or placebo groups (21.9% and 21.0%, respectively [P,0.001 for both]); the differences between allopurinol and placebo at both time points were also statistically significant (P,0.001). Results of 24-hour urine collections are reported in Table 3. The number of determinations for some values vary slightly, because some participants had missing data. No clinically important differences were observed between treatment groups for any variable at baseline or any variable other than uua at 6 months. The change from baseline in the ratio of 24-hour uua/creatinine was determined in a post hoc analysis to explore the possibility that incomplete or inaccurate 24-hour urine collections may have confounded the primary end point results. The mean percent change from baseline to month 6 in the uua/creatinine ratio closely resembled the percent change from baseline in 24-hour uua for the febuxostat (258.2%) and allopurinol (240.4%) groups, whereas it was smaller in the placebo group (20.5%). This result suggests
5 Clin J Am Soc Nephrol 8: ccc ccc, November, 2013 Febuxostat for Hyperuricosuria and Calcium Stones, Goldfarb et al. 5 N=30 N=29 N=30 N=31 N=29 N=31 Figure 2. Percent change from baseline to months 3 and 6 in 24-hour urinary uric acid excretion. a P,0.001 versus placebo. b P=0.008 versus allopurinol. c P=0.003 versus allopurinol. Error bars represent the SD for each data point. Table 2. Change from baseline in stone diameter and number Diameter of largest calcium stone, mm Febuxostat 80 mg Allopurinol 300 mg Placebo Baseline, n Mean (SD) 11.9 (6.3) 9.4 (4.4) 8.2 (3.6) Median Month 6 Mean (SD) 10.9 (6.1) 9.4 (4.0) 8.0 (3.2) Median Percent change from baseline, mean (SD) (28.4) 0.63 (12.6) 3.20 (23.7) Total number of calcium stones Baseline, n Mean (SD) 5.00 (4.0) 6.57 (7.0) 6.00 (6.1) Median Month 6 Mean (SD) 4.94 (5.1) 6.85 (7.4) 6.10 (6.0) Median Change from baseline, mean (SD) (1.6) 0.28 (2.0) 0.10 (1.8) Only participants with data at both baseline and 6 months were included. that incomplete or inaccurate 24-hour urine collections had little impact on the primary results. At both months 3 and 6, the differences in the percent change from baseline in the uua/creatinine ratio were statistically significant (P,0.001) for febuxostat versus allopurinol, febuxostat versus placebo, and allopurinol versus placebo. Safety More than one half of participants reported a treatmentemergent AE (59.6%): 60.6%, 57.6%, and 60.6% in the febuxostat, allopurinol, and placebo groups, respectively. The most frequently reported treatment-emergent AEs by Medical Dictionary for Regulatory Activities High-Level Terms were musculoskeletal and connective tissue pain and discomfort (12.1%), renal lithiasis (8.1%), upper respiratory tract infections (8.1%), headache (6.1%), and edema (5.1%). Only one subject in the placebo group reported a serious AE (severe pain associated with kidney stone), which required hospitalization. Among eight reports of nephrolithiasis (four, three, and one report in the placebo, febuxostat, and allopurinol groups, respectively), including the above-mentioned AEs and one severe AE, two individuals reportedly passed stones (not the index stones based on the month 6 computed tomography), and
6 6 Clinical Journal of the American Society of Nephrology Table 3. Urinary variables at baseline and month 6 and change from baseline to month 6 Urinary Variable Febuxostat 80 mg (n=33) Allopurinol 300 mg (n=33) Placebo (n=33) Calcium (mg/24 h), n Baseline (81.6) (75.5) (98.7) Month (152.3) (230.8) (152.1) CFB to month (158.3) 41.9 (223.2) (128.0) Citrate (mg/24 h), n Baseline (276.8) (353.6) (216.7) Month (307.1) (416.1) (287.9) CFB to month (192.1) (279.3) (268.5) Creatinine (mg/24 h), n Baseline (740.3) (803.1) (563.4) Month (1259.8) (1098.4) (557.7) CFB to month (866.9) (1421.8) (775.1) Magnesium (mg/24 h), n Baseline (53.7) (47.7) (36.7) Month (68.1) (57.0) (58.2) CFB to month (75.8) (58.9) (59.2) Oxalate (mg/24 h), n Baseline 50.0 (23.8) 42.9 (22.3) 41.0 (20.4) Month (19.4) 40.0 (20.6) 36.3 (25.0) CFB to month (22.3) 22.9 (28.1) 24.6 (30.7) ph (24 h), n Baseline 6.1 (0.4) 5.7 (1.0) 6.0 (0.4) Month (1.0) 6.0 (0.4) 5.96 (0.3) CFB to month (1.0) 0.2 (0.1) (0.4) Potassium (meq/24 h), n Baseline 87.2 (39.0) 87.1 (29.2) 73.3 (30.8) Month (71.3) 80.5 (39.4) 70.4 (32.9) CFB to month (69.5) (41.6) 22.9 (37.1) Protein (mg/24 h), n Baseline (308.3) (79.0) (760.6) Month (260.8) (139.4) (1326.0) CFB to month (198.6) 12.0 (108.9) (568.2) Sodium (meq/24 h), n Baseline (85.5) (98.8) (55.1) Month (90.6) (115.1) (97.8) CFB to month (95.8) (143.2) 1.7 (95.8) Sulfate (mmol/24 h), n Baseline 27.6 (13.2) 30.7 (11.3) 26.9 (10.8) Month (14.6) 26.9 (16.0) 20.9 (9.4) CFB to month (15.2) 23.8 (18.6) 25.9 (10.2) Uric acid (mg/24 h), n Baseline (215.5) (251.1) (126.6) Month (250.8) (315.1) (260.7) CFB to month (270.9) (404.0) (282.6) Uric acid (mg/dl), n Baseline 52.0 (17.0) 46.0 (18.1) 49.7 (16.4) Month (15.2) 32.9 (15.3) 45.7 (19.9) CFB to month (20.4) (19.7) 24.0 (25.0) Only participants with data at both baseline and 6 months were included. Data provided as mean (SD). CFB, change from baseline. the remaining six participants experienced symptoms consistent with but not proven to be caused by stones. No participants died during the study, and no elevated hepatic enzyme tests were reported. Three participants prematurely discontinued because of AEs: one subject in the placebo group (musculoskeletal pain) and two participants in the febuxostat group (one participant with viral hepatitis and increased blood creatinine phosphokinase levels and one participant with nausea, vomiting, and renal colic). Discussion This study is the first randomized, multisite, blinded clinical trial designed to evaluate the effect of treatment with the XORI drugs febuxostat and allopurinol in recurrent calcium stone formers with higher uua excretion. Our results show that febuxostat (80 mg) once daily lowered 24-hour uua significantly more than allopurinol (300 mg) in recurrent stone formers with higher uua excretion. After only 6 months of treatment, we did not
7 Clin J Am Soc Nephrol 8: ccc ccc, November, 2013 Febuxostat for Hyperuricosuria and Calcium Stones, Goldfarb et al. 7 observe significant changes in the diameter of the largest stone (determined at baseline), suggesting that these index stones did not get bigger. In addition, only one subject reported acute nephrolithiasis requiring hospitalization, and there were no significant changes in the mean numbers of stones in any treatment arm, suggesting that no new stones large enough to enumerate on MDCT had formed. There was no difference in the number of episodes of renal colic between the three groups, although the study was not powered to detect such a difference. In one of the only other randomized controlled trials to examine the impact of XORI therapy on CaOx stone formation in recurrent stone formers, Ettinger et al. (8) followed 60 hyperuricosuric and normocalciuric participants randomized to receive either allopurinol (100 mg three times daily) or placebo for 6 to 24 months. The allopurinol group experienced significant declines from baseline in sua and uua. New calculus events, defined as the passing of a stone or appearance of stone on x-ray after 6 months of treatment, occurred in 18 participants in the placebo group and 9 participants in the allopurinol group. The mean rate of calculus events was reduced from pretreatment levels by 63.4% and 81.2% in the placebo and allopurinol groups, respectively (P,0.001 for magnitude of change from baseline for both groups). Ettinger et al. (8) concluded that allopurinol could provide clinically important protection for those stone formers. These data suggest that longer duration of treatment with febuxostat could lead to reduced recurrence of CaOx stones in stone formers with higher uua excretion. Although allopurinol is approved for doses up to 800 mg/d for reducing elevated sua in gout, with dose reductions recommended in participants with renal impairment, we used the recommended dose for uua reduction in patients with CaOx stones (18), which is the same total daily dose used in the study by Ettinger et al. (8). If higher doses of allopurinol were used in our study, they may have led to greater uua reductions in that treatment group. There is still some debate as to whether higher uua excretion is a risk factor for CaOx stone formation. In an epidemiologic cohort analysis of 24-hour urine chemistries from 2237 stone formers and 1113 controls, there was no correlation between increasing uua and risk of stone formation. In fact, among men, there was an unexpected observed inverse relationship between lower uua and higher risk for stone formation (19). In another study, the 24-hour urinary excretion of urate was investigated in 467 consecutive stone formers (350 men and 117 women) and 89 healthy controls with no history of stone disease. Men had a higher uua than women, but there was no difference between stone formers and controls (20). Given this doubt and uncertainty about what today constitutes hyperuricosuria, we have referred to our study population as having higher uua excretion. The underlying mechanism by which uric acid may promote CaOx stone formation has been investigated. It was first thought that monosodium urate crystals served as seeds that triggered heterogeneous nucleation of CaOx crystals. Although this finding was shown in inorganic solutions designed to mimic salt concentrations in urine (21), it was not observed in undiluted urine (22). Instead, evidence favors salting out of calcium oxalate (23). Grover et al. (24) showed that, in urine samples with various solute concentrations, there was a dose response relationship between higher amounts of dissolved urate added and greater tendency of the urine to crystallize CaOx, until the saturation point of urate was reached. Analysis of resulting crystals found no evidence of urate crystals. Grover et al. (24) suggested that, in individuals with high urine concentrations of calcium and oxalate, even a slight increase of dissolved urate, within the normouricosuric range, could facilitate precipitation of CaOx crystals (24). Limitations of this study include the treatment duration of 6 months. Other studies that have shown the positive impact of XORI use on recurrent stone rates treated individuals for up to 6 years (6 8). However, in early studies by Worcester and Coe (6) and Coe and Kavalach (7), many individuals ceased to experience kidney stones within 3 months of treatment with allopurinol. We did not observe any significant changes in the mean size of the largest stones in the febuxostat group or increases in mean stone numbers, but 6 months of treatment may not have been long enough to determine if new stone formation or existing stone growth had been deterred. This study did not examine the effects of XORI use on symptomatic stone episodes. Additional long-term studies are needed to assess the effect of treatment with XORIs on reduction in the number of stones, recurrent stone formation, and clinical stone episodes. Another limitation may have been any potential inconsistencies in ph levels across the urine samples. Traditional recommendations for urine processing for the measurement of urate include alkalinization of the urine (25). In urine with low ph, urate will precipitate out of solution. If not all of the urine samples were adequately alkalinized, it could lead to an underestimation of uua levels in our samples. Participants were not prescribed any therapy to alter urine ph as part of the study protocol, and only one subject was taking potassium citrate at enrollment and throughout the duration of the study. At baseline, mean urine ph levels were 6.0, 6.0, and 5.8 in the placebo, febuxostat, and allopurinol groups, respectively. These values are not significantly different than expected in nonstone-forming adults. Therefore, there is no reason to suspect that such an artifact leading to underestimation of uua was different at baseline than at month 3 or 6. There were large SDs for creatinine excretion values, indicating that the 24-hour urine collections were not done in an ideal fashion. Coefficients of variation of urine creatinine excretion do increase with BMI (26); the mean baseline BMI in our population was 32.8 kg/m 2, and therefore, it may have also contributed to the large SD. Our analysis of urine uric acid to creatinine ratios, in part, overcomes the limitations of inaccurate or incomplete collections; despite the inaccurate or incomplete collections, the ratios were consistent with the treatment effects shown by the values for 24- hour uric acid excretion. We cannot rule out the possibility that some of the participants stones were uric acid stones; however, the qualifying index stone for study enrollment and repeated measurement was radio-opaque by the equivalent of a plain x-ray. Some participants had missing data on 24-hour urine collections (Table 3). Finally, the participants may not be typical stone formers, because they had experienced, on average, more than 10 stone episodes and were seen in busy endourology practices.
8 8 Clinical Journal of the American Society of Nephrology In conclusion, 6 months of treatment with febuxostat (80 mg) once daily led to significantly greater declines in uua compared with allopurinol (300 mg) once daily or placebo in hyperuricosuric people with calcium nephrolithiasis. Additional studies of greater duration with greater numbers of participants and additional doses of febuxostat (i.e., 40 mg) and allopurinol are needed to determine if reduction of uua excretion by XORI therapy will reduce the incidence of symptomatic calcium stone recurrence. Acknowledgments The study was funded by Takeda Global Research & Development Center, Inc. Medical writing support was provided by Meryl Gersh of AlphaBioCom, LLC in King of Prussia, PA and funded by Takeda Pharmaceutical International, Inc. These data were presented at the American Society of Nephrology Kidney Week, San Diego, November 2, 2012 and the American College of Rheumatology Annual Meeting, Washington, D.C., November 11, Disclosures D.S.G. has served as a consultant for Takeda Global Research & Development Center, Inc. D.S.G. was involved in all phases of study design and execution, was involved in writing the manuscript, and had access to the full dataset. At the time of study design and execution, P.A.M., L.G., S.C., and L.M. were employees of Takeda Global Research & Development Center, Inc. References 1. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC: Time trends in reported prevalence of kidney stones in the United States: Kidney Int 63: , Scales CD, Jr., Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project: Prevalence of kidney stones in the United States. Eur Urol 62: , Ljunghall S: Incidence of upper urinary tract stones. Miner Electrolyte Metab 13: , Cohen TD, Streem SB, Lammert G: Long-term incidence and risks for recurrent stones following contemporary management of upper tract calculi in patients with a urinary diversion. J Urol 155: 62 65, Worcester EM, Coe FL: Nephrolithiasis. Prim Care 35: , Coe FL, Kavalach AG: Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. NEnglJMed291: , Coe FL: Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med 87: , Ettinger B, Tang A, Citron JT, Livermore B, Williams T: Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 315: , Strauss AL, Coe FL, Parks JH: Formation of a single calcium stone of renal origin. Clinical and laboratory characteristics of patients. Arch Intern Med 142: , Smith MJ: Placebo versus allopurinol for renal calculi. JUrol117: , Becker M, Schumacher HR, Espinoza L, Wells AF, MacDonald P, Lloyd E, Lademacher C: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Res Ther 12: R63, Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353: , Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59: , Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L: Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 45: , Goldfarb DS, MacDonald P, Hunt B, Gunawardhana L: Febuxostat in gout: Serum urate responses in uric acid overproducers vs. underexcretors. J Rheumatol 38:1385 9, Shimizu T, Hori H: The prevalence of nephrolithiasis in patients with primary gout: A cross-sectional study using helical computed tomography. J Rheumatol 36: , Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139: , Allopurinol US: Prescribing Information, Weston, FL, Apotex Corp., Curhan GC, Taylor EN: 24-h uric acid excretion and the risk of kidney stones. Kidney Int 73: , Fellstrom B, Backman U, Danielson BG, Johansson G, Ljunghall S, Wikstrom B: Urinary excretion of urate in renal calcium stone disease and in renal tubular acidification disturbances. JUrol 127: , Grover PK, Ryall RL: The effect of preincubation of seed crystals of uric acid and monosodium urate with undiluted human urine to induce precipitation of calcium oxalate in vitro: Implications for urinary stone formation. Mol Med 8: , Grover PK, Ryall RL: Effect of seed crystals of uric acid and monosodium urate on the crystallization of calcium oxalate in undiluted human urine in vitro. Clin Sci (Lond) 92: , Worcester EM, Coe FL: Clinical practice. Calcium kidney stones. N Engl J Med 363: , Grover PK, Marshall VR, Ryall RL: Dissolved urate salts out calcium oxalate in undiluted human urine in vitro: Implications for calcium oxalate stone genesis. Chem Biol 10: , Ng RH, Menon M, Ladenson JH: Collection and handling of 24- hour urine specimens for measurement of analytes related to renal calculi. Clin Chem 30: , Perry GM, Scheinman SJ, Asplin JR: Weight, age and coefficients of variation in renal solute excretion. Nephron Physiol 122: 13 18, 2012 Received: February 12, 2013 Accepted: June 30, 2013 Published online ahead of print. Publication date available at www. cjasn.org.
24-h uric acid excretion and the risk of kidney stones
http://www.kidney-international.org & 2008 International Society of Nephrology original article 24-h uric acid excretion and the risk of kidney stones GC Curhan 1,2,3 and EN Taylor 1,2 1 Department of
More informationWomen With Gout: Efficacy and Safety of Urate-Lowering With Febuxostat and Allopurinol
Arthritis Care & Research Vol. 64, No. 2, February 2012, pp 256 261 DOI 10.1002/acr.20680 2012, American College of Rheumatology ORIGINAL ARTICLE Women With Gout: Efficacy and Safety of Urate-Lowering
More informationCARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD for the CARES Investigators Calhoun Cardiology Center University
More informationMedical Approach to Nephrolithiasis. Seth Goldberg, MD September 15, 2017 ACP Meeting
Medical Approach to Nephrolithiasis Seth Goldberg, MD September 15, 2017 ACP Meeting DISCLOSURES Seth Goldberg, MD Assistant Professor of Medicine Research support Abbott Kadmon Otsuka Pfizer Introduction
More informationUloric Step Therapy Program
Uloric Step Therapy Program Policy Number: 5.01.584 Last Review: 7/2017 Origination: 7/2014 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for brand
More informationRISK FACTORS AND TREATMENT STRATEGIES FOR URINARY STONES Review of NASA s Evidence Reports on Human Health Risks
Mayo Clinic O Brien Urology Research Center RISK FACTORS AND TREATMENT STRATEGIES FOR URINARY STONES 2017 Review of NASA s Evidence Reports on Human Health Risks John C Lieske, MD July 27, 2017 What types
More informationUrate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout
Philippine Journal of Internal Medicine Meta-Analysis Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout Erika Bianca S. Villazor-Isidro, M.D.*; John Carlo G.
More informationSchool of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PLB SEMINAR
1 School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PLB SEMINAR URINARY (RENAL) STONE FORMATION An Overview What are Urinary (Renal)
More informationPart I: On-line web-based survey of Dalmatian owners GENERAL INFORMATION
Dr. Bartges' final report on the Dal stone survey: Commissioned by the Dalmatian Club of America Foundation (DCAF) Published in the DCA magazine, The Spotter, Summer 2006 Part I: On-line web-based survey
More informationEffective Health Care Program
Comparative Effectiveness Review Number 61 Effective Health Care Program Recurrent Nephrolithiasis in Adults: Comparative Effectiveness of Preventive Medical Strategies Executive Summary Introduction Nephrolithiasis
More informationFebuxostat: a new treatment for hyperuricaemia in gout
Rheumatology 2009;48:ii15 ii19 doi:10.1093/rheumatology/kep088 Febuxostat: a new treatment for hyperuricaemia in gout N. Lawrence Edwards 1 Febuxostat is a new non-purine xanthine oxidase inhibitor that
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationCOMPARATIVE EVALUATION OF EFFICACY AND SAFETY PROFILE OF FEBUXOSTAT WITH ALLOPURINOL IN PATIENTS WITH HYPERURICEMIA AND GOUT
Int. J. Pharm. Med. & Bio. Sc. 2013 P K Agarwal and Bijay Kumar, 2013 Research Paper ISSN 2278 5221 www.ijpmbs.com Vol. 2, No. 4, October 2013 2013 IJPMBS. All Rights Reserved COMPARATIVE EVALUATION OF
More informationNEPHROLITHIASIS Etiology, stone composition, medical management, and prevention
NEPHROLITHIASIS Etiology, stone composition, medical management, and prevention Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Epidemiology Prevalence 2-3%, maybe in
More informationIs the Serum Uric Acid Level Independently Associated with Incidental Urolithiasis?
pissn: 2093-940X, eissn: 2233-4718 Journal of Rheumatic Diseases Vol. 25, No. 2, April, 2018 https://doi.org/10.4078/jrd.2018.25.2.116 Original Article Is the Serum Uric Acid Level Independently Associated
More informationManagement of common uroliths through diet
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Management of common uroliths through diet Author : Marge Chandler Categories : Canine, Companion animal, Feline, Vets Date
More informationUrinary Calculus Disease. Urinary Stones: Simplified Metabolic Evaluation. Urinary Calculus Disease. Urinary Calculus Disease 2/8/2008
Urinary Stones: Simplified Metabolic Evaluation Marshall L. Stoller, M.D. Professor and Vice Chairman Department of Urology University of California San Francisco Incidence: 7-21/10,000 3 men: 1 woman
More informationThe Urate-lowering Efficacy and Safety of Febuxostat in Korean Patients with Gout
Journal of Rheumatic Diseases Vol. 2, No. 4, August 213 http://dx.doi.org/1.478/jrd.213.2.4.223 Original Article The Urate-lowering Efficacy and Safety of in Korean Patients with Gout Sung Hwan Park 1,
More informationFamily History and Age at the Onset of Upper Urinary Tract Calculi
Endourology and Stone Disease Family History and Age at the Onset of Upper Urinary Tract Calculi Yadollah Ahmadi Asr Badr, Samad Hazhir, Kamaleddin Hasanzadeh Introduction: The aim of this study was to
More informationPrincipal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA
SYNOPSIS Issue Date: 06 October 2008 Document No.: EDMS-PSDB-8954363:2. Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name of Active Ingredient(s)
More informationPotential Pharmacologic Treatments for Cystinuria and for Calcium Stones Associated with Hyperuricosuria
Potential Pharmacologic Treatments for Cystinuria and for Calcium Stones Associated with Hyperuricosuria David S. Goldfarb Summary Two new potential pharmacologic therapies for recurrent stone disease
More informationIdentification and qualitative Analysis. of Renal Calculi
Identification and qualitative Analysis of Renal Calculi 1 -Renal Calculi: Kidney stones, renal calculi or renal lithiasis (stone formation) are small, hard deposits that form inside your kidneys. The
More informationN Engl J Med 2018;378: DOI: /NEJMoa Lin, Wan-Ting 2018/06/27
N Engl J Med 2018;378:1200-10. DOI: 10.1056/NEJMoa1710895 Lin, Wan-Ting 2018/06/27 1 Introduction Gout is a chronic illness characterized by hyperuricemia, arthropathy, tophus development, and urolithiasis
More informationUrine Stone Screen requirements
Urine Stone Screen requirements Unique Identifying Index Number LP/PA/CB/CBSP030 Version number 4 Issue Date (this version) 03.08.15 Document Type Accreditation or Licensing Standard to which this applies
More informationHHS Public Access Author manuscript Hepatology. Author manuscript; available in PMC 2017 March 01.
Febuxostat-Induced Acute Liver Injury Matt Bohm, DO, Raj Vuppalanchi, MD, Naga Chalasani, MD, and Drug Induced Liver Injury Network (DILIN) Department of Medicine, Indiana University School of Medicine,
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationCase presentation. serum uric acid = 11.5 mg/dl 24-hour uric acid excretion = 300 mg
GOUT 55 y/o male 12 hours pain in my big toe & ankle went to bed last night feeling fine felt as if had broken toe this morning similar problems in right ankle & left wrist Case presentation lab studies
More informationInitial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment
Initial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment of Patients in the Midst of an Acute Gout Attack Investor
More informationAlkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy and percutaneous nephrolithotomy
Clinical Urology Alkaline citrate and stone recurrence International Braz J Urol Vol. 37 (5): 611-616, September - October, 2011 Alkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy
More informationMEDICAL STONE MANAGEMENT MADE EASY PRACTICAL ADVICE
MEDICAL STONE MANAGEMENT MADE EASY PRACTICAL ADVICE Comprehensive Kidney Stone Center at Duke University Medical Center Durham, North Carolina Glenn M. Preminger, M.D. UCLA State-of-the Art Urology 02
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationJournal of Advanced Scientific Research
Bijoy Kumar Panda et al, J Adv Scient Res, 2012, 3(2): 03-11 3 Journal of Advanced Scientific Research Available online through http://www.sciensage.info/jasr ISSN 0976-9595 Review Article Febuxostat,
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationRecurrent stone formers-metabolic evaluation: a must investigation
International Surgery Journal Bhangu GS et al. Int Surg J. 2017 Jan;4(1):86-90 http://www.ijsurgery.com pissn 2349-3305 eissn 2349-2902 Original Research Article DOI: http://dx.doi.org/10.18203/2349-2902.isj20163972
More informationMetabolic Stone Work-Up For Stone Prevention. Dr. Hazem Elmansy, MD, MSC, FRCSC Assistant Professor, NOSM, Urology Department
Metabolic Stone Work-Up For Stone Prevention Dr. Hazem Elmansy, MD, MSC, FRCSC Assistant Professor, NOSM, Urology Department Faculty/Presenter Disclosure Slide Faculty: Hazem Elmansy Relationships with
More informationFebuxostat now subsidised on Special Authority
Gout update: Febuxostat now subsidised on Special Authority 38 Febuxostat was added to the New Zealand Pharmaceutical Schedule on 1 June, 2014. It is now available as a third-line preventive treatment
More informationLhanoo Gunawardhana 1*, Michael A. Becker 2, Andrew Whelton 3, Barbara Hunt 1, Majin Castillo 1 and Kenneth Saag 4,5
Gunawardhana et al. Arthritis Research & Therapy (2018) 20:99 https://doi.org/10.1186/s13075-018-1593-0 RESEARCH ARTICLE Open Access Efficacy and safety of febuxostat extended release and immediate release
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationAlterations of Renal and Urinary Tract Function
Alterations of Renal and Urinary Tract Function Chapter 29 Urinary Tract Obstruction Urinary tract obstruction is an interference with the flow of urine at any site along the urinary tract The obstruction
More informationPathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis
Kidney International, Vol. 22 (1982), pp. 366 3 70 Pathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis STEPHANIE MILLMAN, AMY L. STRAUSS, JOAN H. PARKS, AND FREDRIC
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationLesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout
Lesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout Briefing Document for the Arthritis Advisory Committee Meeting Date: 23 October 215 Ardea
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A
More informationLimitations of Use: (1) Duzallo is not recommended for the treatment of asymptomatic hyperuricemia.
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.63 Subject: Duzallo Page: 1 of 5 Last Review Date: December 8, 2017 Duzallo Description Duzallo (lesinurad
More informationCost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout
Cost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout The NCPE has issued a recommendation regarding the cost-effectiveness of Lesinurad (Zurampic ) in combination with
More informationFebuxostat: a safe and effective therapy for hyperuricemia and gout
DRUG EVALUATIO Febuxostat: a safe and effective therapy for hyperuricemia and gout atasha Jordan & Geraldine M McCarthy Author for correspondence Mater Misericordiae University Hospital, Eccles St. Dublin
More informationPRODUCT INFORMATION UROCIT -K. Wax matrix tablets
PRODUCT INFORMATION UROCIT -K Wax matrix tablets NAME OF DRUG Potassium Citrate CAS number- 6100-05-6 The empirical formula of potassium citrate is K 3 C 6 H 5 0 7.H 2 O, and its structural formula is:
More informationDrugs Used to Treat Gout. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drugs Used to Treat Gout Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Gout is a metabolic disease characterized by recurrent episodes of acute arthritis
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationDiet and fluid prescription in stone disease
http://www.kidney-international.org & 2006 International Society of Nephrology mini review Diet and fluid prescription in stone disease EN Taylor 1 and GC Curhan 1,2 1 Renal Division, Department of Medicine,
More informationUrolithiasis. Ali Kasraeian, MD, FACS Kasraeian Urology Advanced Laparoscopic, Robotic & Minimally Invasive Urologic Surgery
Urolithiasis Ali Kasraeian, MD, FACS Kasraeian Urology Advanced Laparoscopic, Robotic & Minimally Invasive Urologic Surgery Urolithiasis: Why should we care? Affects 5% of US men and women Men twice as
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationKidney Stone Update. Epidemiology of Kidney Stones. Lifetime Risk of Kidney Stone
Kidney Stone Update Michael Emmett MD Baylor University Medical Center Dallas, Texas Epidemiology of Kidney Stones Incidence About 0.3% Prevalence 10% Men 12% Women 8% Hospitalization Peak Age Stone Composition
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationCorrespondence between stone composition and urine supersaturation in nephrolithiasis
Kidney International, Vol. 51 (1997), pp. 894 900 Correspondence between stone composition and urine supersaturation in nephrolithiasis JOAN H. PARKS, MARK COWARD, and REDRIC L. COE Program in Nephrology,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationTreatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFructose, Uric Acid and Hypertension in Children and Adolescents
Fructose, Uric Acid and Hypertension in Children and Adolescents Daniel I. Feig, MD, PhD, MS Director, Division of Nephrology Department of Pediatrics University of Alabama, Birmingham Topics for Discussion
More informationGout 2.0. Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy
Gout 2.0 Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy Case 48 year old man presents with swollen, painful left toe that started overnight. Didn t hurt when he went to bed. No
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Effect of Diet Orange soda on urinary lithogenicity Permalink https://escholarship.org/uc/item/27x8w1h4 Journal Urological Research, 40(3)
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationGout -revisited. Shrenik Shah
Gout -revisited Shrenik Shah definition Monosodium urate (MSU) crystal deposition episodic and later persistent joint inflammation and tophi All MSU crystal deposition- broader definition EULAR- European
More informationKrystexxa. Krystexxa (pegloticase) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.14 Subject: Krystexxa Page: 1 of 5 Last Review Date: March 16, 2018 Krystexxa Description Krystexxa
More informationQuaseem et coll. Ann Intern Med 2014
Dietary and Pharmacologic Management to prevent Recurrent Nephrolithiasis in Adults A Clinical Practice Guideline From the American College of Physicians Introduction Approximately 80% of adults with kidney
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationArticle. Stone Composition as a Function of Age and Sex
CJASN epress. Published on October 2, 2014 as doi: 10.2215/CJN.05660614 Article Stone Composition as a Function of Age and Sex John C. Lieske,* Andrew D. Rule,* Amy E. Krambeck, James C. Williams, Eric
More informationUrologic Stone Disease. Urologic Stone Disease. Urologic Stone Disease. Urologic Stone Disease. Urologic Stone Disease 5/7/2010
Diagnosis and Treatment Stephen E. Strup MD William Farish Professor and Chief of Urology Director of Minimally Invasive Urologic Surgery University of Kentucky I will not cut, even for the stone, but
More informationA Phase 1/2 Trial of Lumasiran (ALN-GO1), an Investigational RNAi Therapeutic for Primary Hyperoxaluria Type 1
A Phase 1/2 Trial of Lumasiran (ALN-GO1), an Investigational RNAi Therapeutic for Primary Hyperoxaluria Type 1 OxalEurope Meeting Naples, Italy 8 June 2018 2018 Alnylam Pharmaceuticals, Inc. Background
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationJapanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson-Zachrisson, 3
More informationZurampic. (lesinurad) New Product Slideshow
Zurampic (lesinurad) New Product Slideshow Introduction Brand name: Zurampic Generic name: Lesinurad Pharmacological class: URAT1 inhibitor Strength and Formulation: 200mg; tablets Manufacturer: Ironwood
More informationSponsor/Company: sanofi-aventis Drug substance: Elitek/Fasturtec (rasburicase, SR29142)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: sanofi-aventis Drug
More informationClinical Pearls in Renal Medicine
Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 24 June 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 24 June 2009 ADENURIC 80 mg, film-coated tablets B/28 (CIP code: 385 724-4) B/84 (CIP code: 572 820-3) ADENURIC 120
More informationEffect of BMI and Urinary ph on Urolithiasis and Its Composition
Saudi J Kidney Dis Transpl 2013;24(1):60-66 2013 Saudi Center for Organ Transplantation Original Article Saudi Journal of Kidney Diseases and Transplantation Effect of BMI and Urinary ph on Urolithiasis
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationDecreased renal function among adults with a history of nephrolithiasis: A study of NHANES III
Kidney International, Vol. 67 (2005), pp. 685 690 Decreased renal function among adults with a history of nephrolithiasis: A study of NHANES III DANIEL L. GILLEN,ELAINE M. WORCESTER, and FREDRIC L. COE
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury Introduction In recent years, acute kidney injury (AKI) has gained increasing recognition as a major risk factor for the development of chronic kidney disease (CKD). The
More informationThe Nuts and Bolts of Kidney Stones. Soha Zouwail Consultant Chemical Pathology UHW Renal Training Day 2019
The Nuts and Bolts of Kidney Stones Soha Zouwail Consultant Chemical Pathology UHW Renal Training Day 2019 Urinary Calculi Prevalence and incidence of kidney stones increasing across the world Environmental
More informationEQUILIBRIUM VERSUS SUPERSATURATED URINE HYPOTHESIS IN CALCIUM SALT UROLITHIASIS: A NEW THEORETICAL AND PRACTICAL APPROACH TO A CLINICAL PROBLEM
Scanning Microscopy Vol. 13, No. 2-3, 1999 (Pages 261-265) 0891-7035/99$5.00+.25 Scanning Microscopy International, Chicago Equilibrium (AMF O Hare), model for IL calcium 60666 USA salt urolithiasis EQUILIBRIUM
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationRheumatoid arthritis, seronegative spondylarthritides and gout. György Nagy
Rheumatoid arthritis, seronegative spondylarthritides and gout György Nagy Dec 4, 2017 Rheumatoid arthritis Rheumatoid arthritis Chronic, progressive, autoimmune disorder of the joints with extra-articular
More informationComposition: Each Tablet contains. Pharmacokinetic properties:
Composition: Each Tablet contains Torsemide 5/10/20/40/100mg Pharmacokinetic properties: Torsemide is well absorbed from the gastrointestinal tract. Peak serum concentrations are achieved within 1 hour
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationORIGINAL ARTICLE INTRODUCTION
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 59, No. 11, November 15, 2008, pp 1540 1548 DOI 10.1002/art.24209 2008, American College of Rheumatology ORIGINAL ARTICLE Effects of Versus Allopurinol
More informationSAT24 Supersaturation Profile, 24 Hour, Urine
1-800-533-1710 SAT24 Supersaturation Profile, 24 Hour, Urine Patient ID Patient Name SAMPLEREPORT, SAT24 NORMAL Birth Date 1976-05-13 Gender M Age 40 Order Number Client Order Number Ordering Physician
More informationDr. Mehmet Kanbay Department of Medicine Division of Nephrology Istanbul Medeniyet University School of Medicine Istanbul, Turkey.
The uric acid dilemma: causal risk factor for hypertension and CKD or mere bystander? Mehmet Kanbay, Istanbul, Turkey Chairs: Anton H. van den Meiracker, Rotterdam, The Netherlands Claudia R.C. Van Roeyen,
More informationPredictors of post-transplant CKD MBD 2695
Predictors of post-transplant CKD MBD 2695 Nephrol Dial Transplant (2011) 26: 2695 2700 doi: 10.1093/ndt/gfq769 Advance Access publication 1 February 2011 Clinical characteristics of potential kidney donors
More informationEvaluation of different urinary constituent ratios in renal stone formers
Available online at www.scholarsresearchlibrary.com Annals of Biological Research, 2010, 1 (3) : 50-55 (http://scholarsresearchlibrary.com/archive.html) ISSN 0976-1233 CODEN (USA): ABRNBW Evaluation of
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationCase studies. Stephen Mark Rob Walker
Case studies Stephen Mark Rob Walker Case 1 31 yr old woman with 3 rd UTI. E coli Frequency and dysuria Asymptomatic after treatment Recurrent UTI Lower tract symptoms Coliforms Asymptomatic after treatment
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More information